| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M | ||
| $100M |
Buys | $349,999,986 | 1 | 2 |
Sells | $16,504,285 | 41 | 98 |
| Roivant Sciences Ltd. | 1 | $350M | 0 | $0 | $350M | |
| Susman Robert Graham | director | 0 | $0 | 1 | $67,979 | $-67,979 |
| Hughes Douglas J. | director | 0 | $0 | 1 | $348,665 | $-348,665 |
| Pande Atul | director | 0 | $0 | 5 | $424,650 | $-424,650 |
| Venker Eric | Chief Executive Officer | 0 | $0 | 3 | $581,424 | $-581,424 |
| Van Tuyl Christopher | Chief Legal Officer | 0 | $0 | 8 | $1.46M | $-1.46M |
| Girao Tiago | Chief Financial Officer | 0 | $0 | 4 | $1.6M | $-1.6M |
| Gloria Melanie | Chief Operating Officer | 0 | $0 | 8 | $1.67M | $-1.67M |
| Stout Jay S | Chief Technology Officer | 0 | $0 | 9 | $2.39M | $-2.39M |
| Fromkin Andrew J. | director | 0 | $0 | 2 | $7.96M | $-7.96M |
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and …
Over the last 12 months, insiders at Immunovant, Inc. have bought $350M and sold $16.5M worth of Immunovant, Inc. stock.
On average, over the past 5 years, insiders at Immunovant, Inc. have bought $188.12M and sold $8.54M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Roivant Sciences Ltd. () — $350M.
The last purchase of 16,666,666 shares for transaction amount of $350M was made by Roivant Sciences Ltd. () on 2025‑12‑12.
| 2026-10-28 | Sale | Girao Tiago | Chief Financial Officer | 6,606 0.0031% | $28.50 | $188,271 | -1.07% | |
| 2026-10-21 | Sale | Stout Jay S | Chief Technology Officer | 2,595 0.0013% | $28.94 | $75,099 | +2.33% | |
| 2026-10-07 | Sale | Gloria Melanie | Chief Operating Officer | 2,241 0.0011% | $32.06 | $71,846 | -10.39% | |
| 2026-10-07 | Sale | Stout Jay S | Chief Technology Officer | 3,809 0.0018% | $32.06 | $122,117 | -10.39% | |
| 2026-10-07 | Sale | Van Tuyl Christopher | Chief Legal Officer | 1,327 0.0006% | $32.06 | $42,544 | -10.39% | |
| 2026-10-02 | Sale | Venker Eric | Chief Executive Officer | 3,506 0.0017% | $34.11 | $119,590 | -13.86% | |
| 2026-09-23 | Sale | Van Tuyl Christopher | Chief Legal Officer | 2,846 0.0015% | $36.36 | $103,481 | -14.82% | |
| 2026-08-28 | Sale | Pande Atul | director | 1,500 0.0008% | $43.27 | $64,905 | -18.98% | |
| 2026-08-20 | Sale | Gloria Melanie | Chief Operating Officer | 3,056 0.0015% | $44.16 | $134,953 | -24.16% | |
| 2026-07-24 | Sale | Pande Atul | director | 1,500 0.0007% | $39.80 | $59,700 | -5.20% | |
| 2026-07-23 | Sale | Girao Tiago | Chief Financial Officer | 6,798 0.0033% | $38.69 | $263,015 | -4.74% | |
| 2026-07-23 | Sale | Stout Jay S | Chief Technology Officer | 2,857 0.0014% | $38.69 | $110,537 | -4.74% | |
| 2026-07-08 | Sale | Gloria Melanie | Chief Operating Officer | 2,036 0.001% | $39.55 | $80,532 | -4.19% | |
| 2026-07-08 | Sale | Stout Jay S | Chief Technology Officer | 3,487 0.0017% | $39.55 | $137,925 | -4.19% | |
| 2026-07-08 | Sale | Van Tuyl Christopher | Chief Legal Officer | 1,206 0.0006% | $39.55 | $47,702 | -4.19% | |
| 2026-07-02 | Sale | Venker Eric | Chief Executive Officer | 3,092 0.0015% | $38.48 | $118,980 | -0.34% | |
| 2026-06-26 | Sale | Girao Tiago | Chief Financial Officer | 10,000 0.0049% | $38.46 | $384,600 | -0.60% | |
| 2026-06-26 | Sale | Gloria Melanie | Chief Operating Officer | 17,714 0.0086% | $38.31 | $678,604 | -0.60% | |
| 2026-06-26 | Sale | Stout Jay S | Chief Technology Officer | 40,000 0.0195% | $38.31 | $1.53M | -0.60% | |
| 2026-06-26 | Sale | Van Tuyl Christopher | Chief Legal Officer | 17,824 0.0087% | $38.31 | $682,887 | -0.60% |
| Roivant Sciences Ltd. | 113317007 54.8611% | $3.29B | 7 | 0 | +21.17% | |
| Hughes Douglas J. | director | 120773 0.0585% | $3.51M | 1 | 2 | <0.0001% |
| Pande Atul | director | 116731 0.0565% | $3.39M | 2 | 7 | +99.21% |
| Fromkin Andrew J. | director | 74382 0.036% | $2.16M | 1 | 4 | <0.0001% |
| WONG RODERICK | Chief Executive Officer | 902498 0.4369% | $26.21M | 22 | 0 | +118.39% |
| Butchko Julia G. | Chief Development Officer | 440959 0.2135% | $12.81M | 1 | 22 | <0.0001% |
| MIGAUSKY GEORGE V | director | 109808 0.0532% | $3.19M | 1 | 1 | <0.0001% |
$67,892,722 | 138 | 28.28% | $6.25B | |
$224,662,742 | 52 | 32.03% | $5.65B | |
$613,304,943 | 46 | 11.85% | $6.22B | |
$11,583,737 | 45 | 49.75% | $4.66B | |
Immunovant, Inc. (IMVT) | $477,065,869 | 34 | 82.05% | $6B |
| Increased Positions | 117 | +61.58% | 23M | +23.66% |
| Decreased Positions | 81 | -42.63% | 9M | -9.81% |
| New Positions | 40 | New | 9M | New |
| Sold Out Positions | 27 | Sold Out | 3M | Sold Out |
| Total Postitions | 226 | +18.95% | 109M | +13.85% |
| Fmr Llc | $381,643.00 | 7.33% | 14.73M | -4M | -20.8% | 2025-09-30 |
| Deep Track Capital, Lp | $252,074.00 | 4.84% | 9.73M | +228,845 | +2.41% | 2025-09-30 |
| Vanguard Group Inc | $176,883.00 | 3.4% | 6.83M | -199,128 | -2.83% | 2025-09-30 |
| Armistice Capital, Llc | $151,211.00 | 2.9% | 5.84M | +636,000 | +12.23% | 2025-09-30 |
| Blackrock, Inc. | $148,678.00 | 2.86% | 5.74M | -110,049 | -1.88% | 2025-09-30 |
| Baker Bros. Advisors Lp | $141,414.00 | 2.72% | 5.46M | 0 | 0% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $133,817.00 | 2.57% | 5.16M | -2M | -24.92% | 2025-09-30 |
| Point72 Asset Management, L.P. | $89,184.00 | 1.71% | 3.44M | +105,828 | +3.17% | 2025-09-30 |
| State Street Corp | $74,948.00 | 1.44% | 2.89M | +62,544 | +2.21% | 2025-09-30 |
| Two Seas Capital Lp | $71,564.00 | 1.37% | 2.76M | +509,268 | +22.61% | 2025-09-30 |